Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24093122 | 0.91 | KMT2A (0.61) | KDM1AMAOAMAOBKMT2AMEN1 | |
| Formic Acid SCHEMBL5082488 | 0.90 | KDM1A (0.48) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL17307262 | 0.88 | KDM1A (0.47) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL25091239 | 0.88 | KDM1A (0.47) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL22570235 | 0.87 | KDM1A (0.46) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL22570236 | 0.87 | KDM1A (0.46) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL22570243 | 0.87 | KDM1A (0.46) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL24267576 | 0.87 | KDM1A (0.46) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL15672056 | 0.87 | KDM1A (0.46) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL15647813 | 0.87 | KDM1A (0.46) | KDM1AMAOAMAOBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | claimed |
| EP-1620403-B1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-28 | — | — | EP | claimed |
| WO-2019056120-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2019-03-28 | — | — | WO | disclosed |
| US-8470813-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBVIE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010122580-A2 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| US-7683084-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBOTT LABORATORIES (US) | 2010-03-23 | — | — | US | disclosed |
| CN-101479262-A | Thiazoline and oxazoline derivatives and their methods of use | ABBOTT LAB (US) | 2009-07-08 | — | — | CN | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| CN-1649870-A | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD (CH) | 2005-08-03 | — | — | CN | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004105762-A1 | MEDICAL USE OF DIAZABICYCLONONENE DERIVATIVES AS INHIBITORS OF PARASITE ASPARTIC PROTEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105738-A2 | USE OF TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004096769-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | KDM1A 3777/4885MAOA 289/4885MAOB 330/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | KDM1A 1409/4885MAOA 994/4885MAOB 579/4885 |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | OXA1L, CYP3A7, ABAT | KDM1A 3895/4885MAOA 1006/4885MAOB 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.